Recently, cepharanthine has been revealed to block the binding of the TSH receptor peptide (TSHR.132) to HLA- DRβ1-Arg74 and, thus, to inhibit T-cell activation and cytokine response in a humanized, HLA-DR3 expressing, mouse model of Graves’ disease [68]. Here, TSHR is linked to Graves disease.